Paper3293160
Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
Berman JD. Rev Infect Dis, 1988. Cited by 329 papers, by iCite.
Cite this record
ConductScience Library. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Papers, record 3293160. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3293160
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimony | Major topic |
| Antiprotozoal Agents | Major topic |
| Leishmania | Major topic |
| Leishmaniasis | Major topic |
| Leishmaniasis, Visceral | Major topic |
| Animals | |
| Chemical Phenomena | |
| Chemistry | |
| Energy Metabolism | |
| Humans | |
| Lipid Metabolism | |
| Polyamines | |
| Purines |
Source PubMed
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 329 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41835577 | Nucleoside Analogue with Thymidine Nucleobase Inhibits Leishmania infantum and Depolarizes the Plasma Membrane Potential In Vitro. | ACS Omega | 2026 | https://conductscience.org/library/papers/41835577 | PubMed |
| 41023664 | Long-term trends of visceral leishmaniasis incidence and mortality in India 1990-2019: an application of joinpoint and age-period-cohort analysis. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41023664 | PubMed |
| 39981004 | Design, synthesis and biological activity of peptidyl β-nitrostyrenes as cysteine protease inhibitors against Leishmania donovani. | RSC Adv | 2025 | https://conductscience.org/library/papers/39981004 | PubMed |
| 39752369 | Progress in antileishmanial drugs: Mechanisms, challenges, and prospects. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/39752369 | PubMed |
| 38716320 | The Effectiveness of Perovskia abrotanoides Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial. | J Res Pharm Pract | 2023 | https://conductscience.org/library/papers/38716320 | PubMed |
| 36964053 | Small-molecule correctors and stabilizers to target p53. | Trends Pharmacol Sci | 2023 | https://conductscience.org/library/papers/36964053 | PubMed |
| 36422934 | Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline. | Trop Med Infect Dis | 2022 | https://conductscience.org/library/papers/36422934 | PubMed |
| 36211958 | Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36211958 | PubMed |
| 35457536 | Availability, Toxicology and Medical Significance of Antimony. | Int J Environ Res Public Health | 2022 | https://conductscience.org/library/papers/35457536 | PubMed |
| 34245362 | Potential of Piper spp. as a source of new compounds for the leishmaniases treatment. | Parasitol Res | 2021 | https://conductscience.org/library/papers/34245362 | PubMed |
| 32325815 | In Vitro Anti-Leishmanial Effect of Metallic Meso-Substituted Porphyrin Derivatives against Leishmania braziliensis and Leishmania panamensis Promastigotes Properties. | Molecules | 2020 | https://conductscience.org/library/papers/32325815 | PubMed |
| 31430693 | The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis. | Int J Parasitol Drugs Drug Resist | 2019 | https://conductscience.org/library/papers/31430693 | PubMed |
| 28615844 | The antileishmanial effects of Lowsonia inermis and Cedrus libani on Leishmania major promastigotes: an in vitro study. | J Parasit Dis | 2017 | https://conductscience.org/library/papers/28615844 | PubMed |
| 28242356 | Glycyrrhizic acid attenuates growth of Leishmania donovani by depleting ergosterol levels. | Exp Parasitol | 2017 | https://conductscience.org/library/papers/28242356 | PubMed |
| 24824136 | Novel triphenylantimony(V) and triphenylbismuth(V) complexes with benzoic acid derivatives: structural characterization, in vitro antileishmanial and antibacterial activities and cytotoxicity against macrophages. | Molecules | 2014 | https://conductscience.org/library/papers/24824136 | PubMed |
| 23263387 | Molecular, cytological, and immunocytochemical study and kDNA sequencing of laryngeal Leishmania infantum infection. | Parasitol Res | 2013 | https://conductscience.org/library/papers/23263387 | PubMed |
| 22201704 | Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. | Oncotarget | 2011 | https://conductscience.org/library/papers/22201704 | PubMed |
| 22114501 | Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. | Int J Nanomedicine | 2011 | https://conductscience.org/library/papers/22114501 | PubMed |
| 22091408 | Use of antimony in the treatment of leishmaniasis: current status and future directions. | Mol Biol Int | 2011 | https://conductscience.org/library/papers/22091408 | PubMed |
| 21716553 | Leishmaniasis of the lip diagnosed by lymph node aspiration and treated with a combination of oral ketaconazole and intralesional sodium stibogluconate. | Indian J Dermatol | 2011 | https://conductscience.org/library/papers/21716553 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3293160
GET https://conductscience.org/api/papers/v1/3293160/cited_by?page=2